H.C. Wainwright raised the firm’s price target on Armata Pharmaceuticals (ARMP) to $15 from $9 and keeps a Buy rating on the shares after the company announced that AP-SA02 received Qualified Infectious Disease Product designation from the FDA. The firm says the designation strengthens the drug’s regulatory framework ahead of the Phase 3 readout. The news is “incremental regulatory support” as Armata prepares to initiate its Phase 3 superiority study in the second half of 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARMP:
- Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy
- Armata Pharmaceuticals receives FDA QIDP designation for AP-SA02
- Armata Extends Innoviva Credit, Warrants and Voting Pact
- Armata Pharmaceuticals: FDA-Endorsed Phase 3 Path and Potential QIDP Upside Support Buy Rating on AP-SA02
- Armata Wins FDA Support to Advance Bacteriophage to Phase 3